SynthesisFrontiers in immunology2023
Comorbidity in bullous pemphigoid: up-date and clinical implications.
Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin.The American journal of tropical medicine and hygiene · 2026Article
- Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies.American journal of clinical dermatology · 2026Review
- Factors associated with prolonged hospital stay in patients with autoimmune bullous diseases treated at an in-patient dermatology service.Skin health and disease · 2026Article
- A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease.International journal of molecular sciences · 2026Article
- Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.Postepy dermatologii i alergologii · 2026Article
- Peptide Epitopes of NC16A BP180 in the Diagnostics of Bullous Pemphigoid.JID innovations : skin science from molecules to population health · 2025Article
- A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.Dermatology and therapy · 2025Review
- Autoimmune bullous diseases: pathogenesis and clinical management.Molecular biomedicine · 2025Review
- Analysis of rare events in healthcare intervention using department of defense data: intravenous immune globulin therapy for bullous pemphigoid.BMC medical research methodology · 2025Article
- Prevalence of comorbidities and thromboembolic events in individuals with Autoimmune Bullous diseases.Archives of dermatological research · 2025Article
- Associated factors related to production of autoantibodies and dermo-epidermal separation in bullous pemphigoid.Archives of dermatological research · 2025Review
- Comorbidities and autoimmune disease associations in patients with Bullous Pemphigoid: a cross-sectional study of the all of us database.Archives of dermatological research · 2024Article
- Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review.Journal of clinical medicine · 2024Review
- Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.Acta dermato-venereologica · 2024Article
- Associations between bullous pemphigoid and comorbidities: A Swedish nationwide cohort study of 5,738 patients.Journal of multimorbidity and comorbidityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous pemphigoid. A better understanding why distinct diseases are more frequent in bullous pemphigoid patients may lead to new pathophysiological insights and - as a consequence - result in better patient care. The association of bullous pemphigoid with neurological and psychiatric diseases is well known and confirmed by several case-control studies. Association with further diseases such as malignancy and metabolic diseases are still discussed controversially. In recent years new relationships between bullous pemphigoid and autoimmune as well as inflammatory skin diseases have been reported. This review provides a systematic overview on studies addressing comorbidity in bullous pemphigoid patients. Increasing the awareness of both, common and rare comorbid diseases, may enable clinicians to optimize patient support and individualized treatment of bullous pemphigoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.